FIELD: chemistry.SUBSTANCE: invention relates to field of organic chemistry, namely to heterocyclic compound of formula (I) or its racemate, enantiomer, diastereoisomer and their mixture, as well as to their pharmaceutically acceptable salt, where A is selected from the group, consisting of carbon atom or nitrogen atom when A represents carbon atom, R1 represents C1-C6-alkoxyl R2 represents cyano when A represents nitrogen atom, R1 hydrogen atom or C1-C6-alkoxyl where said C1-C6-alkoxyl is optionally additionally substituted with one C1-C6-alkoxyl group R2 is absent R3 represents radical, which has the formula given below: or , where D represents phenyl, where phenyl is optionally additionally substituted with one or two halogen atoms T represents -O(CH2)r- L represents pyridyl R4 and R5 each represents hydrogen atom R6 and R7 each is independently selected from hydrogen atom or hydroxyl R8 represents hydrogen atom R9 represents hydrogen atom or C1-C6-alkyl r equals 1 and n equals 2 or 3. Invention also relates to intermediate compound of formula (IA), method of obtaining compound of formulae (I) and (IA), pharmaceutical composition based on formula (I) compound and method of its obtaining and to application of formula (I) compound.EFFECT: novel heterocyclic compounds, inhibiting activity with respect to receptor tyrosine kinases EGFR or receptor tyrosine kinases HER-2 are obtained.18 cl, 12 ex, 4 tblИзобретение относится к области органической химии, а именно к гетероциклическому соединению формулы (I) или к его рацемату, энантиомеру, диастереоизомеру и их смеси, а также к их фармацевтически приемлемой соли, где A выбран из группы, состоящей из атома углерода или атома азота когда A представляет собой атом углерода, R1 представляет собой C1-C6-алкоксил R2 представляет собой циано когда A представляет собой атом азота, R1 представляет собой атом водорода или C1-C6-алкоксил где указанный C1-C6-алкоксил необязательно дополнительно замещен одной группой C1-C6-алкок
